Early MS Treatments Show Different Effects on Relapses and Brain Damage, Not Disability

A new study reveals that IV medications targeting B cells in the immune system reduce relapses by 62% compared to oral pills commonly prescribed for early-stage multiple sclerosis. While B-cell targeting therapies show promise in controlling disease activity and reducing brain scarring, researchers found no significant difference in disability progression between the two treatment approaches. This finding suggests that early intervention with IV immunotherapies may offer better protection against relapses in MS patients, though long-term disability outcomes remain comparable. The research highlights the importance of individualized treatment planning for MS patients in their early disease stages.